10-Q: Bioventus Inc. Reports Mixed Q2 Results Amidst Strategic Divestiture and Litigation Settlement

Bioventus Inc. announced its second quarter 2024 results, highlighting revenue growth alongside a significant impairment charge related to a planned divestiture and costs associated with a shareholder litigation settlement.

Summary

• Bioventus Inc. reported a net loss of $32.1 million for the second quarter of 2024, compared to a net loss of $4.7 million in the same period last year.
• Net sales for the quarter increased by 10.3% to $151.2 million, up from $137.1 million in the second quarter of 2023.
• The company recorded a significant impairment charge of $31.9 million related to its Advanced Rehabilitation Business, which is planned for divestiture.
• Selling, general, and administrative expenses increased to $94.8 million, primarily due to $12.5 million in costs related to a shareholder litigation settlement.
• Adjusted EBITDA for the quarter was $34.5 million, compared to $28.2 million in the prior year period.
• The company is in the process of divesting its Advanced Rehabilitation Business to simplify its structure and improve liquidity.
• Bioventus received FDA clearance for its OSTEOAMP Cannula delivery system and EU certification for its Exogen Bone Stimulation System.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the significant net loss, impairment charge, and litigation costs. While there are positive aspects like revenue growth and new product approvals, the financial challenges and ongoing legal issues weigh heavily on the overall outlook.

Positives

• Net sales increased by 10.3% year-over-year, indicating strong demand for the company's products.
• Adjusted EBITDA increased to $34.5 million, showing improved operational performance.
• The company received FDA clearance for the OSTEOAMP Cannula delivery system, which is expected to drive future growth.
• The EU certification for the Exogen Bone Stimulation System allows the company to expand its market reach.
• The planned divestiture of the Advanced Rehabilitation Business is expected to improve liquidity and simplify the company's structure.

Negatives

• The company reported a net loss of $32.1 million for the quarter, a significant increase from the $4.7 million loss in the same period last year.
• A $31.9 million impairment charge was recorded due to the planned divestiture of the Advanced Rehabilitation Business.
• Selling, general, and administrative expenses increased significantly due to shareholder litigation settlement costs.
• The company is facing ongoing legal challenges, including shareholder derivative lawsuits.

Risks

• The company's ability to successfully divest its Advanced Rehabilitation Business is subject to ongoing contract negotiations.
• The company is exposed to risks related to its debt covenants and may be required to repay its indebtedness.
• The company is subject to securities class action litigation and may face similar or other litigation in the future.
• The company's long-term growth depends on its ability to develop, acquire, and commercialize new products.
• The proposed down classification of non-invasive bone growth stimulators by the FDA could increase competition.
• The company faces risks related to intellectual property matters and potential supply chain disruptions.

Future Outlook

The company expects to continue focusing on its core businesses, including Pain Treatments and Surgical Solutions, while divesting non-core assets to improve liquidity and simplify its structure. The company plans a limited launch of OSTEOAMP Cannula in the fourth quarter of 2024.

Management Comments

• Management is focused on developing and commercializing clinically differentiated, cost efficient and minimally invasive treatments.
• The potential divestiture of the Advanced Rehabilitation Business is expected to simplify the company's business structure and improve liquidity.
• The company is working to reduce long-term debt obligations with the proceeds from the divestiture.
• Management believes that current cash, cash equivalents, future cash flows from operating activities and cash available under the 2019 Credit Facility will be sufficient to meet anticipated cash needs for at least 12 months.

Industry Context

The medical device industry is experiencing ongoing regulatory changes, such as the EU MDR, which requires companies to adapt their clinical evidence and reporting processes. Bioventus is navigating these changes while also focusing on innovation and market expansion. The company's strategic divestiture and focus on core businesses reflect a broader trend in the industry towards streamlining operations and improving profitability.

Comparison to Industry Standards

• Bioventus's revenue growth of 10.3% is solid compared to some of its peers in the medical device industry, but the net loss and impairment charges are concerning.
• Companies like Stryker and Zimmer Biomet, which are larger and more diversified, often show more stable profitability, but they also have different product mixes and market positions.
• The company's focus on minimally invasive treatments aligns with industry trends, but its ability to compete effectively will depend on its innovation and commercialization efforts.
• The litigation costs are a significant drag on profitability, and this is not typical for most medical device companies, which usually have lower legal expenses.
• The divestiture of the Advanced Rehabilitation Business is a strategic move to focus on core competencies, similar to what other companies do to improve their financial health.

Legal Proceedings

• The company is involved in a shareholder class action lawsuit, which has reached a settlement agreement of $15.3 million, subject to court approval.
• The company is also facing derivative shareholder lawsuits, which are currently stayed pending resolution of the class action lawsuit.
• The company was previously involved in a Bioness stockholder litigation, which has been dismissed.

Stakeholder Impact

• Shareholders are impacted by the net loss, impairment charge, and litigation costs, but may benefit from the strategic divestiture and focus on core businesses.
• Employees may be affected by the divestiture of the Advanced Rehabilitation Business.
• Customers will benefit from the new product launches and continued focus on innovation.
• Creditors are impacted by the company's debt obligations and the potential for improved liquidity through divestiture.

Next Steps

• The company will continue contract negotiations for the divestiture of its Advanced Rehabilitation Business.
• The company plans a limited launch of the OSTEOAMP Cannula delivery system in the fourth quarter of 2024.
• The company will seek court approval for the settlement agreement related to shareholder litigation.
• The company will continue to monitor and comply with the financial covenants under the Amended 2019 Credit Agreement.

Key Dates

Keywords

Bioventus, medical devices, orthopedics, bone healing, pain management, surgical solutions, restorative therapies, divestiture, litigation, FDA clearance, EU certification, OSTEOAMP, Exogen